Revenue +20% to $2.2M in FY2025. Gross margin expanded 840 basis points to 62.5%. E-commerce revenue +88%; now more than half of total. Active deployments in NYC, Chicago, Boston, Baltimore, LA County, and San Francisco.
SenesTech reported $2.2M in FY2025 revenue. 20 percent growth year-over-year from $1.86M. Gross margin expanded 840 basis points to 62.5 percent from 54.1 percent in FY2024. Q3 2025 was a record $690K, up 43 percent year-over-year. Q2 2025 was a record $625K, up 36 percent. E-commerce revenue grew 88 percent in FY2025 and now represents more than half of total revenue. Municipal deployments grew 139 percent year-over-year in Q3 2025.
The active municipal client list reads like a top-ten U.S. city population ranking: New York City, Chicago, Boston, Baltimore, Los Angeles County, San Francisco. These are institutional procurement customers; they evaluated the product, ran pilots, and signed recurring contracts. Institutional procurement cycles are slow to start but durable once signed. The municipal revenue base is the most defensible part of the business.
The Human Translation: The Subscription Rodent Control Service. ContraPest works by reducing rodent fertility rather than killing them. The population declines over time. To maintain the effect, the customer keeps buying the product. That is a subscription revenue model for pest control; recurring, EPA-registered, and not easily replaced by generic alternatives that would need their own registration process.
The adjusted EBITDA loss improved to $5.3M in FY2025 from $5.8M in FY2024; moving in the right direction but still loss-making. Cash and short-term investments were $10.2M at September 30, 2025. At the current burn rate, the runway (how long current cash lasts at the current burn rate) is meaningful but not unlimited. Revenue needs to continue compounding to reduce the loss rate.
The ESG tailwind is structural: anticoagulant rodenticides are under increasing regulatory pressure, major food retailers are restricting pesticide use in supply chains, and institutional ESG frameworks prefer non-lethal pest management. SenesTech's EPA registration is a genuine competitive moat. Generics cannot enter without completing their own registration; a process that takes years.
The municipal client roster is the most compelling evidence that ContraPest works in real-world deployment conditions. New York City, Chicago, Boston, Baltimore, Los Angeles County, and San Francisco are not small municipalities experimenting with novel approaches. These are major metropolitan governments with established pest management programs, procurement processes, and performance evaluation frameworks. Each of these cities evaluated ContraPest through pilot programs before committing to ongoing contracts. The 139 percent year-over-year growth in municipal deployments during Q3 2025 tells you that the pilot-to-contract conversion rate is high and that new cities are entering the pipeline. Municipal procurement is slow to start; bureaucratic approval processes, budget allocation cycles, vendor qualification requirements; but once a municipality signs a contract, the renewal rate is historically high because switching pest management approaches mid-program creates operational disruption that city managers actively avoid.
The EPA registration is a genuine competitive moat that deserves more analytical attention than it typically receives. ContraPest is an EPA-registered fertility control product for Norway rats and roof rats. EPA registration for a pesticide or pest control product requires extensive toxicological testing, environmental impact assessment, efficacy demonstration, and manufacturing quality documentation. The registration process takes years and costs millions of dollars. A generic competitor cannot simply copy the formulation and bring it to market; they must complete their own EPA registration process from scratch, including their own toxicological studies and efficacy trials. This regulatory barrier to entry is the functional equivalent of a patent in terms of competitive protection, and unlike patents, EPA registrations do not expire on a fixed timeline. They are maintained through ongoing compliance and periodic review. SenesTech has invested years and significant capital to achieve and maintain this registration, and the result is a product that no competitor can legally sell without completing their own multi-year regulatory process.
The e-commerce channel growth of 88 percent in FY2025 represents a structural diversification of the revenue base away from municipal contracts toward commercial and agricultural customers who purchase directly. E-commerce revenue now represents more than half of total revenue, which means the company is no longer dependent exclusively on the slow municipal procurement cycle for growth. Commercial customers; food processing facilities, agricultural operations, warehousing and logistics companies, and commercial property management firms; have shorter purchasing cycles and can order directly through the SenesTech online platform. This channel provides higher-frequency revenue with lower customer acquisition costs than the municipal channel, which requires in-person presentations, pilot programs, and budget approval processes.
The ESG and regulatory tailwind is structural and accelerating. Anticoagulant rodenticides; the traditional approach to rodent control, are under increasing regulatory pressure at both the state and federal level. California has implemented restrictions on second-generation anticoagulant rodenticides due to documented secondary poisoning of wildlife, including endangered species. Major food retailers and food service companies are restricting pesticide use in their supply chains as part of ESG commitments and consumer safety protocols. Institutional ESG frameworks increasingly prefer non-lethal pest management approaches that do not create environmental contamination or secondary poisoning risks. ContraPest fits precisely into this evolving regulatory and commercial framework; it controls rodent populations without killing them, without environmental contamination, and without secondary poisoning of non-target species. Every regulatory restriction on traditional rodenticides expands the addressable market for ContraPest.
The unit economics at 62.5 percent gross margin (the share of revenue left after direct costs) are constructive for a physical product company at this revenue scale. The 840 basis point margin expansion from FY2024 to FY2025 reflects improved manufacturing efficiency, better raw material procurement, and the leverage effect of spreading fixed production costs across higher volume. If the revenue trajectory continues; from $2.2M toward $3M-plus, the gross margin should continue improving because the manufacturing cost structure has significant fixed components that do not scale linearly with volume. The adjusted EBITDA loss improved from $5.8M to $5.3M, moving in the right direction but still substantial relative to the revenue base. The path to EBITDA breakeven requires either continued revenue growth at 20-plus percent annually or a significant reduction in operating expenses. The revenue growth path is more likely given the active municipal pipeline and the e-commerce channel acceleration.
The total addressable market for urban rodent management is enormous by any measure. The U.S. pest control industry generates approximately $23 billion in annual revenue, with rodent control representing a meaningful segment. However, TAM figures for an early-stage company with $2.2M in revenue are less analytically useful than the specific addressable market within the current customer base. There are approximately 90 cities in the United States with populations above 250,000. SenesTech currently has active deployments in six of them. The expansion from six to twelve to twenty municipal customers; each with annual contract values that grow as deployment zones expand; is the near-term revenue growth math. Each new city represents not just a single contract but an expanding relationship as the initial pilot zone proves effective and the municipality extends coverage to additional neighborhoods.
The subscription-like nature of the ContraPest revenue model is an underappreciated structural advantage. Traditional rodenticides are one-time purchases; a customer buys poison, deploys it, and the rodent population is temporarily reduced before rebounding. ContraPest works by reducing fertility, which means the effect is gradual and sustained but requires continuous deployment to maintain the population reduction. This creates a recurring revenue relationship: the customer must continue purchasing and deploying ContraPest to maintain the fertility control effect. If they stop, the rodent population rebounds within a few reproductive cycles. This is functionally equivalent to a subscription model for pest control; the customer cannot achieve lasting results without ongoing purchases. For SenesTech, this means every new municipal or commercial customer represents a stream of future revenue, not a one-time sale. The lifetime value of a municipal customer that deploys ContraPest across expanding zones over multiple years is dramatically higher than the initial contract value.
The international market opportunity has not been materially pursued but represents a future growth vector. Urban rodent management is not a uniquely American problem; every major global city faces rodent population challenges, and many face them with even fewer tools than U.S. cities because regulatory frameworks in some jurisdictions have already banned anticoagulant rodenticides entirely. The European Union, for example, has implemented restrictions on second-generation anticoagulant rodenticides that are more stringent than current U.S. federal regulations. A fertility control product with EPA registration and documented U.S. municipal deployments would have a compelling regulatory and commercial case for international markets where the alternatives are more restricted. SenesTech has not meaningfully pursued international expansion at this revenue scale, but the regulatory tailwind that supports the U.S. business exists globally, and the addressable market expands significantly when evaluated beyond U.S. borders.
The management team execution through the transition from research-stage to commercial-stage operations has been steady if not spectacular. CEO Joel Fruendt has navigated the company through the EPA registration process, built the municipal sales channel from zero to six major cities, launched the e-commerce direct channel that now represents half of revenue, and expanded gross margins by 840 basis points in a single fiscal year. The company is still pre-profitable with a $5.3M adjusted EBITDA loss, which means the execution needs to continue improving; but the directional indicators are uniformly positive. Revenue is growing at 20 percent. Margins are expanding. Municipal deployments are increasing. E-commerce is scaling. Operating losses are narrowing. None of these metrics individually are sufficient to declare victory, but collectively they describe a business that is moving systematically from development-stage economics toward commercial viability. The next 12 months will determine whether the trajectory bends toward profitability or whether the growth rate is insufficient to close the gap between revenue and the operating cost base.
The product development pipeline extends beyond ContraPest into next-generation formulations and delivery systems that could expand the addressable market further. Evolv is a soft bait matrix formulation designed for deployment in environments where liquid bait stations are impractical; agricultural settings, outdoor urban environments, and areas where traditional bait station infrastructure is difficult to maintain. A soft bait formulation expands the deployment scenarios from controlled indoor and semi-outdoor environments to open agricultural and urban landscapes where rodent populations cause crop damage and disease transmission. If Evolv achieves EPA registration and commercial launch, it approximately doubles the addressable deployment scenarios for SenesTech fertility control technology. The R&D investment in next-generation formulations is funded by the existing ContraPest revenue base, meaning the pipeline development does not require dilutive capital raises at current burn rates.
The brand positioning of ContraPest as a humane, environmentally responsible rodent management solution resonates with a growing segment of institutional and commercial buyers whose procurement decisions are influenced by sustainability criteria. Major food retailers including Whole Foods and institutional food service companies have implemented policies restricting or eliminating the use of anticoagulant rodenticides in their facilities and supply chains. Property management companies serving ESG-conscious tenants face similar pressure to adopt non-toxic pest management. These commercial buyers represent a customer segment that is willing to pay a premium for a solution that aligns with their sustainability commitments and brand positioning. ContraPest is not just an alternative to poison; it is a positive brand story that procurement managers can cite in their sustainability reports.
The public health narrative is the long-term demand driver that transcends any single municipal contract. Rodent-borne diseases; leptospirosis, hantavirus, salmonella, and others; represent genuine public health risks in urban environments. Climate change is expanding rodent habitats and extending breeding seasons, increasing urban rodent populations in measurable ways. Every public health event linked to rodent infestation; and these events occur regularly in major cities. Reinforces the case for investment in rodent population management. ContraPest is the only tool that addresses the population at a systemic level rather than killing individual rodents who are immediately replaced by breeding. The fundamental value proposition; reduce the population permanently rather than endlessly killing and replacing; is sound biology and increasingly recognized by public health officials.
Dossiers, weekly roundup editions, and podcast notes. Free. No paywall. Unsubscribe anytime.